Literature DB >> 27506662

Impact of Flap Reconstruction on Radiotoxicity After Salvage Surgery and Reirradiation for Recurrent Head and Neck Cancer.

Allen S Ho1, Zachary S Zumsteg2, Annika Meyer2, Nadeem Riaz2, Rahmatullah Rahmati1, Dennis H Kraus1, Colleen McCarthy3, Richard J Wong1, Jatin P Shah1, Nancy Y Lee4,5.   

Abstract

BACKGROUND: Recurrent head and neck malignancies remain a therapeutic challenge. Tissue transfer, in addition to defect coverage and prevention of wound complications, may potentially decrease radiotoxicity. We evaluated radiation toxicity and survival outcomes of patients who underwent salvage surgery with reirradiation, comparing primary closure to flap reconstruction.
METHODS: Retrospective outcomes analysis of recurrent head and neck squamous cell carcinoma (HNSCC) patients treated with curative intent by salvage surgery (± flap reconstruction) and reirradiation from 1996 to 2011. Recurrent stage, reirradiation modality, chemotherapy use, and toxicities were evaluated.
RESULTS: Of 96 patients, 59 had primary closure, whereas 37 underwent flap reconstruction (26 free, 11 pedicled). Median radiation and reirradiation doses were 66 Gy and 60 Gy, respectively. Comparing nonflap and flap patients, there was no significant difference in acute mild toxicities (100 vs. 100 %, p = 1.0) or acute severe toxicities (33.9 vs. 37.8 %, p = 0.83). Nonflap patients experienced significantly greater incidence of both late mild toxicities (81.4 vs. 54.1 %, p = 0.006) and late severe toxicities (47.5 vs. 21.6 %, p = 0.02). Overall survival at 5 years was equivalent (33.1 vs. 34.7 %, p = 0.88). Free flap patients had greater delays to postoperative reirradiation and treatment package times compared with pedicled flap patients but no meaningful difference in survival outcomes.
CONCLUSIONS: Vascularized tissue potentially helps offset late toxicities associated with a second radiation course in recurrent head and neck cancer patients. In these selected patients, flap coverage may confer functional benefits and improve the long-term radiotoxicity profile.

Entities:  

Mesh:

Year:  2016        PMID: 27506662      PMCID: PMC5271365          DOI: 10.1245/s10434-016-5492-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

Review 1.  Is the pathology of radiation injury different in small vs large blood vessels?

Authors:  L F Fajardo
Journal:  Cardiovasc Radiat Med       Date:  1999 Jan-Mar

2.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Authors:  Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

Review 3.  Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much?

Authors:  Allen M Chen; Theodore L Phillips; Nancy Y Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-01       Impact factor: 7.038

4.  Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck.

Authors:  David I Rosenthal; Li Liu; Jason H Lee; Neha Vapiwala; Ara A Chalian; Gregory S Weinstein; Irina Chilian; Randal S Weber; Mitchell Machtay
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

5.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

6.  Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer.

Authors:  John P Kostrzewa; William P Lancaster; Tim A Iseli; Renee A Desmond; William R Carroll; Eben L Rosenthal
Journal:  Laryngoscope       Date:  2010-02       Impact factor: 3.325

7.  Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

Authors:  Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

8.  Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.

Authors:  François Janot; Dominique de Raucourt; Ellen Benhamou; Christophe Ferron; Gilles Dolivet; René-Jean Bensadoun; Marc Hamoir; Bernard Géry; Morbize Julieron; Marine Castaing; Etienne Bardet; Vincent Grégoire; Jean Bourhis
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

9.  Postoperative reirradiation for mucosal head and neck squamous cell carcinomas.

Authors:  Tim A Iseli; Claire E Iseli; Eben L Rosenthal; Jimmy J Caudell; Sharon A Spencer; J Scott Magnuson; Angelia N Smith; William R Carroll
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-11

10.  Practical and theoretical considerations in study design for detecting gene-gene interactions using MDR and GMDR approaches.

Authors:  Guo-Bo Chen; Yi Xu; Hai-Ming Xu; Ming D Li; Jun Zhu; Xiang-Yang Lou
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

View more
  2 in total

1.  CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma.

Authors:  Huzheng Yan; Zhiqiang Mo; Zhanwang Xiang; Dailin Rong; Yanlin Zhang; Guanyu Chen; Zhihui Zhong; Fujun Zhang; Fei Gao
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

2.  Double-island anterolateral thigh free flap used in reconstruction for salvage surgery for locally recurrent head and neck carcinoma.

Authors:  Di Deng; Jun Liu; Fei Chen; Dan Lv; Weigang Gan; Linke Li; Ji Wang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.